Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 16/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 2/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | MST1R | Q04912 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4521249 | 0.88 | FYN (0.42) | METFYN | |
| SCHEMBL4524820 | 0.85 | MET (0.44) | METTGFBR1FEN1KITSRC | |
| SCHEMBL1656765 | 0.84 | MET (0.60) | MET | |
| SCHEMBL1660251 | 0.84 | MET (0.60) | MET | |
| SCHEMBL1659861 | 0.84 | MET (0.60) | MET | |
| SCHEMBL1192218 | 0.77 | MET (0.41) | METSRCKDR | |
| SCHEMBL1659625 | 0.75 | MET (0.59) | METFEN1KITSRCPDGFRA | |
| SCHEMBL1659674 | 0.75 | MET (0.59) | METFEN1KITSRCPDGFRA | |
| SCHEMBL1656965 | 0.74 | FYN (0.42) | METFYN | |
| SCHEMBL3435586 | 0.73 | MET (0.60) | METKITSRCPDGFRAAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822468-B2 | 3-Methyl-imidazo[1,2-b]pyridazine derivatives | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | claimed |
| US-20090264406-A1 | 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | NOVARTIS AG | 2009-10-22 | — | — | US | claimed |
| US-8822468-B2 | 3-Methyl-imidazo[1,2-b]pyridazine derivatives | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-20090264406-A1 | 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | NOVARTIS AG | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264406-A1 | 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | MET, ERBB2, ALK | MET 1/4885TGFBR1 556/4885FEN1 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.